NAXIA Discovery (formerly IASO Discovery) is a TechBio company developing next-generation oligonucleotide therapeutics. Built as a spin-off from over 20 years of academic and translational research, NAXIA combines deep expertise in oligonucleotide chemistry with a proprietary discovery platform spanning design, synthesis, conjugation, and formulation.
NAXIA Discovery operates an open and collaborative platform, partnering with academic institutions, biotechs, and industry players through services, co-development, licensing, and spin-off creation.
In parallele, we are developping a first-in-class synthetic G-quadruplex technology introduces a novel mechanism of action to modulate oncogenic gene expression, offering new therapeutic possibilities for treatment-resistant cancers.
With strong scientific leadership and a hybrid business model, NAXIA Discovery aims to become a European reference in oligonucleotide drug discovery and innovation.
